This selective PPARγ modulator (SPPARγM) and others14 had partial agonist activity and showed increased insulin sensitivity and robust glucose-lowering activity with a reduction of the adverse effects observed with PPARγ full agonists, whatever the animal model of diabetes. This evidence concerns the gene PPARG and diabetes mellitus.